OPC-28326

Research use only, not for human use.

OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55?nM, respectively.

OPC-28326 is a selective peripheral vasodilator and an angatonist of α2-adrenergic receptor, with Ki of 2040, 285, and 55?nM for α2A-, α2B- and α2C-adrenoceptors, respectively.

OPC-28326 enhances endothelial tube formation and promotes microvessel growth. OPC-28326 induces phosphorylation of eNOS and Akt in HAECs in a dose dependent-manner, while it does not affect total amounts of eNOS and Akt. OPC-28326 (1-100?μM) and yohimbine (10-1000?nM) causes a rightward shift in the concentration-response curve of clonidine.

OPC-28326 augments blood flow recovery in murine hindlimb ischemia. OPC-28326 significantly increases the number of histologically detectable capillaries in the ischemic leg. OPC-28326 has no beneficial effects on blood flow recovery in eNOS?/? mice. OPC-28326 (3-30?mg/kg, i.v.) and yohimbine causes dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920. OPC-28326 does not affect on the mydriasis in rats.

——

GPCR/G Protein

Adrenergic Receptor

Adrenergic Receptor

——

——

167626-17-7

421.58

C26H35N3O2

>98% (HPLC)

——

C(=O)(C1=CC(C)=C(NC(CC)=O)C(C)=C1)N2CCC(N(CCC3=CC=CC=C3)C)CC2

——

(-20℃)

With Ice Pack

≥ 2 years